Hydralazine Indications
Hydralazine is indicated for two primary conditions: (1) heart failure with reduced ejection fraction (HFrEF), specifically in combination with isosorbide dinitrate, and (2) hypertensive emergencies requiring acute blood pressure reduction.
Heart Failure with Reduced Ejection Fraction (HFrEF)
The combination of hydralazine with isosorbide dinitrate is a guideline-directed medical therapy for HFrEF, demonstrating a 43% relative risk reduction in all-cause mortality 1. This represents one of the most substantial mortality benefits among HFrEF therapies, with a number needed to treat (NNT) of 7 patients over 36 months to prevent one death 1.
Dosing for HFrEF:
- Starting dose: 20-37.5 mg hydralazine three times daily (combined with 20 mg isosorbide dinitrate)
- Target dose: 75 mg hydralazine three times daily (combined with 40 mg isosorbide dinitrate)
- Maximum dose: Up to 300 mg hydralazine total daily in divided doses 1
This combination is particularly valuable as part of quadruple therapy for HFrEF, alongside ACE inhibitors/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.
Hypertensive Emergencies
Hydralazine is FDA-approved for acute blood pressure reduction in hypertensive emergencies when intravenous administration is required 2.
IV dosing for hypertensive emergencies:
- Initial dose: 10 mg via slow IV infusion (maximum initial dose 20 mg)
- Repeat: Every 4-6 hours as needed 2
Critical Limitations in Hypertensive Emergencies
Hydralazine is NOT a first-line agent for most hypertensive emergencies due to its unpredictable response and prolonged duration of action 2. Blood pressure begins decreasing within 10-30 minutes, but effects last 2-4 hours, making titration difficult 2.
Preferred over hydralazine: Nicardipine, labetalol, or other titratable IV agents are superior for most hypertensive emergencies 2.
Specific appropriate use: Hydralazine remains useful in acute coronary syndrome with acute pulmonary edema, though it should not be used in volume-depleted patients 2.
Important Contraindication: Asymptomatic Hypertension
Do NOT use IV hydralazine for asymptomatic blood pressure elevations in hospitalized patients. Recent data shows 69% of IV hydralazine use in inpatient settings lacks appropriate indications 3. This inappropriate use leads to hypotension, acute kidney injury, and ICU transfers without improving outcomes 3, 4. Oral antihypertensives are the appropriate choice for non-emergent hypertension.
Critical Safety Considerations
Cardiac Precautions
Hydralazine causes myocardial stimulation that can precipitate anginal attacks, ECG changes of ischemia, and myocardial infarction 5. Use with extreme caution in suspected coronary artery disease.
The drug increases pulmonary artery pressure in mitral valvular disease and should be avoided in this population 5.
Monitoring Requirements
For chronic therapy, obtain baseline and periodic monitoring of:
- Complete blood counts (risk of hemolytic anemia, leukopenia, agranulocytosis, purpura)
- Antinuclear antibody titers (risk of drug-induced lupus syndrome)
- Monitor even in asymptomatic patients 5
Peripheral Neuropathy
Hydralazine has an antipyridoxine effect. Add pyridoxine supplementation if paresthesias, numbness, or tingling develop 5.
Drug Interactions
- MAO inhibitors: Use with extreme caution
- Other IV antihypertensives (especially diazoxide): Risk of profound hypotensive episodes requiring continuous monitoring for several hours 5
Pregnancy Considerations
Hydralazine is Pregnancy Category C with teratogenic effects in animal studies (cleft palate, facial/cranial bone malformations) 5. Despite this, it remains commonly used for severe hypertension in pregnancy and preeclampsia due to decades of clinical experience, though data on long-term outcomes is limited.